Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
February 08, 2024
With several replenishment campaigns set for 2024-2025, a fundraising pileup is on the horizon. Close to a dozen major development funds—including the World Bank’s International Development Association (IDA), thematic funds like Gavi, and new entities like the Loss and Damage Fund—could aim to raise...
Jul
20
2023
VIRTUAL
10:00—11:00 AM ET / 3:00-4:00 PM BST
June 14, 2023
Join the Center for Global Development for a virtual panel discussion reflecting on lessons learned from COVAX for future global and regional response efforts to ensure rapid and equitable access to vaccines and other medical countermeasures.
Blog Post
June 05, 2023
Recent CGD events have shown several bright spots for the evidence-informed policy agenda, demonstrating leadership commitment to evidence generation and use. The new World Bank president, Ajay Banga, called for the institution to deepen its role as a knowledge bank in a recent speech at CGD. Newly ...
CGD NOTES
June 05, 2023
The World Bank’s lending function is important and irreplaceable. But providing countries with an important source of financing and investing in evidence do not have to be in tension. The role of evaluation should shift from an assessment function to one in which evaluation is a central tool of pro...
CGD NOTES
March 20, 2023
With global challenges high on the international agenda and financing set to increase in the coming years, a big push on evidence, backed by dedicated resources, is essential. This note makes the case for a reinvigorated evidence agenda to boost the impact of financing for development and global pub...
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Mar
7
2023
VIRTUAL
9:30—10:45 AM Eastern Time (US and Canada)
February 27, 2023
Following promising clinical trial results, the first oral antiviral treatments for COVID-19 received emergency use authorization in late 2021. Since then, manufacturers, global health funders, and other partners have focused on ramping up global supply, including via test-and-treat pilot programs. ...
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.